Leerink Partnrs Issues Negative Outlook for Humana Earnings

Humana Inc. (NYSE:HUM - Free Report) - Stock analysts at Leerink Partnrs lowered their FY2025 earnings per share estimates for shares of Humana in a research note issued to investors on Tuesday, February 11th. Leerink Partnrs analyst W. Mayo now forecasts that the insurance provider will post earnings of $16.51 per share for the year, down from their prior forecast of $16.86. The consensus estimate for Humana's current full-year earnings is $16.11 per share. Leerink Partnrs also issued estimates for Humana's Q2 2026 earnings at $5.51 EPS, Q4 2026 earnings at ($1.08) EPS, FY2026 earnings at $15.81 EPS, FY2027 earnings at $27.79 EPS, FY2028 earnings at $36.69 EPS and FY2029 earnings at $45.87 EPS.

Several other equities research analysts have also recently commented on the stock. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $283.00 target price on shares of Humana in a research report on Wednesday, February 12th. Wells Fargo & Company lowered their price objective on shares of Humana from $387.00 to $290.00 and set an "overweight" rating for the company in a report on Monday, November 4th. Piper Sandler upped their target price on Humana from $270.00 to $288.00 and gave the stock a "neutral" rating in a report on Wednesday, January 15th. Barclays raised their target price on Humana from $255.00 to $270.00 and gave the company an "equal weight" rating in a research note on Thursday. Finally, Truist Financial upped their price target on Humana from $260.00 to $290.00 and gave the stock a "hold" rating in a research note on Monday, January 6th. Nineteen investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, Humana presently has an average rating of "Hold" and an average price target of $293.05.

Humana Trading Up 0.3 %

NYSE:HUM traded up $0.73 during trading hours on Thursday, hitting $253.61. The company had a trading volume of 2,386,047 shares, compared to its average volume of 1,515,752. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. The stock has a 50-day moving average price of $271.27 and a 200 day moving average price of $292.96. The company has a market capitalization of $30.54 billion, a PE ratio of 22.46, a price-to-earnings-growth ratio of 2.11 and a beta of 0.56. Humana has a 52 week low of $213.31 and a 52 week high of $406.46.

Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping analysts' consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 13.20% and a net margin of 1.18%.

Institutional Trading of Humana

Hedge funds have recently bought and sold shares of the stock. Pinnacle Wealth Management Advisory Group LLC lifted its position in shares of Humana by 3.6% during the 4th quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,070 shares of the insurance provider's stock valued at $272,000 after buying an additional 37 shares in the last quarter. Atlas Brown Inc. lifted its holdings in Humana by 0.6% during the fourth quarter. Atlas Brown Inc. now owns 6,352 shares of the insurance provider's stock valued at $1,611,000 after purchasing an additional 38 shares in the last quarter. Moors & Cabot Inc. boosted its position in shares of Humana by 2.5% in the third quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider's stock worth $519,000 after purchasing an additional 40 shares during the period. Mather Group LLC. increased its stake in shares of Humana by 21.0% in the fourth quarter. Mather Group LLC. now owns 236 shares of the insurance provider's stock worth $60,000 after purchasing an additional 41 shares in the last quarter. Finally, Capital Advisors Ltd. LLC increased its stake in shares of Humana by 26.1% in the fourth quarter. Capital Advisors Ltd. LLC now owns 208 shares of the insurance provider's stock worth $53,000 after purchasing an additional 43 shares in the last quarter. Institutional investors own 92.38% of the company's stock.

Insider Buying and Selling at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of the company's stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the sale, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. This represents a 31.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.32% of the stock is owned by corporate insiders.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.